The litigation centers on the period between August 9, 2024, and March 25, 2026, during which ADMA Biologics allegedly utilized channel stuffing to fabricate revenue growth. Plaintiffs contend the company failed to disclose problematic related-party transactions and lacked necessary internal controls. These omissions, the suit claims, left investors with a distorted picture of the firm's true operational stability.
In section Releases
ADMA Biologics Faces Securities Fraud Class Action Over Revenue Claims
Investors are lining up to join a securities fraud class action against ADMA Biologics following allegations that the company artificially inflated its stock price. The lawsuit, filed in the wake of a scathing short-seller report, claims the firm misled shareholders regarding its financial health and distribution practices between 2024 and 2026.
The market’s reaction was swift and punishing. On March 24, 2026, Culper Research released a report detailing the alleged irregularities, including the use of an undisclosed distributor, Genesis BioPharma. The revelation triggered a two-day sell-off that erased 31.6% of the company's value. Confidence further eroded on March 26, when Cantor Fitzgerald downgraded the stock, contributing to an additional 13.9% decline. Hagens Berman partner Reed Kathrein noted that the firm is actively investigating how these distribution channels were misrepresented to the public. Shareholders seeking to participate as lead plaintiffs have until August 10, 2026, to file their claims.
Comments (0)
No comments yet. Be the first!